Literature DB >> 20634244

Depression and cognitive impairment in newly diagnosed systemic lupus erythematosus.

Michelle Petri1, Mohammad Naqibuddin, Kathryn A Carson, Daniel J Wallace, Michael H Weisman, Stephen L Holliday, Margaret Sampedro, Patricia A Padilla, Robin L Brey.   

Abstract

OBJECTIVE: Cognitive impairment is present in 80% of patients with systemic lupus erythematosus (SLE) 10 years after diagnosis. The natural history of cognitive dysfunction in newly diagnosed SLE is unknown. We examined the association of depression and cognitive performance in newly diagnosed SLE.
METHODS: A multicenter cohort of 111 patients newly diagnosed (within 9 months) with SLE underwent cognitive function testing using an automated battery [Automated Neuropsychological Assessment Metrics (ANAM)] with 9 subtests. Depression was measured using the Calgary Depression Scale (CDS).
RESULTS: The patient cohort was 97.3% female, 55.9% white, 15.3% African American, 20.7% Hispanic, mean age 37.8 years, mean education 15.2 years. CDS score ranged from 0 to 18 (mean 5.0 ± 4.6). CDS score did not differ by age, sex, ethnicity, or prednisone dose. Higher Krupp Fatigue Severity Scale scores and presence of fibromyalgia were significantly associated with higher CDS score (p < 0.001; p = 0.006, respectively). Depressed patients, defined by a CDS score > 6, had significantly poorer performance on 5 ANAM throughput measures: code substitution (p = 0.03), continuous performance (p = 0.02), matching-to-sample (p = 0.04), simple reaction time (p = 0.02), and the Sternberg memory test (p = 0.04). Adjusting for age, sex, ethnicity, education, and prednisone dose, a higher CDS score remained significantly associated with poorer performance on 3 measures, but the association was slightly attenuated for code substitution and matching-to-sample. Depression was not associated with mathematical or spatial processing.
CONCLUSION: Depression, a modifiable risk factor, is associated with significantly poorer function in several cognitive domains in patients newly diagnosed with SLE. Treatment of depression when the CDS score is greater than 6 may improve cognitive functioning and should be further studied.

Entities:  

Mesh:

Year:  2010        PMID: 20634244     DOI: 10.3899/jrheum.091366

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  37 in total

1.  Anti-NR2 antibodies, blood-brain barrier, and cognitive dysfunction.

Authors:  Gaurav Gulati; Philip H Iffland; Damir Janigro; Bin Zhang; Michael E Luggen
Journal:  Clin Rheumatol       Date:  2016-06-29       Impact factor: 2.980

2.  Primary Sjogren's syndrome: cognitive symptoms, mood, and cognitive performance.

Authors:  B M Segal; B Pogatchnik; E Holker; H Liu; J Sloan; N Rhodus; K L Moser
Journal:  Acta Neurol Scand       Date:  2011-06-09       Impact factor: 3.209

Review 3.  Systemic lupus erythematosus: Diagnosis and clinical management.

Authors:  Andrea Fava; Michelle Petri
Journal:  J Autoimmun       Date:  2018-11-16       Impact factor: 7.094

4.  Comparison of systemic lupus erythematosus patients and healthy individuals in terms of autobiographical memory, mood, and cognitive emotion regulation.

Authors:  Mahshid Taherzadeh; Mahgol Tavakoli
Journal:  Cogn Process       Date:  2020-06-03

5.  Peripheral and central mechanisms of fatigue in inflammatory and noninflammatory rheumatic diseases.

Authors:  Roland Staud
Journal:  Curr Rheumatol Rep       Date:  2012-12       Impact factor: 4.592

Review 6.  Lupus brain fog: a biologic perspective on cognitive impairment, depression, and fatigue in systemic lupus erythematosus.

Authors:  Meggan Mackay
Journal:  Immunol Res       Date:  2015-12       Impact factor: 2.829

Review 7.  Anxiety and Mood Disorders in Systemic Lupus Erythematosus: Current Insights and Future Directions.

Authors:  Annaliese Tisseverasinghe; Christine Peschken; Carol Hitchon
Journal:  Curr Rheumatol Rep       Date:  2018-11-12       Impact factor: 4.592

8.  Decreased SMG7 expression associates with lupus-risk variants and elevated antinuclear antibody production.

Authors:  Yun Deng; Jian Zhao; Daisuke Sakurai; Andrea L Sestak; Vadim Osadchiy; Carl D Langefeld; Kenneth M Kaufman; Jennifer A Kelly; Judith A James; Michelle A Petri; Sang-Cheol Bae; Marta E Alarcón-Riquelme; Graciela S Alarcón; Juan-Manuel Anaya; Lindsey A Criswell; Barry I Freedman; Diane L Kamen; Gary S Gilkeson; Chaim O Jacob; Joan T Merrill; Patrick M Gaffney; Kathy Moser Sivils; Timothy B Niewold; Rosalind Ramsey-Goldman; John D Reveille; R Hal Scofield; Anne M Stevens; Susan A Boackle; Luis M Vilá; I I Woong Sohn; Seung Lee; Deh-Ming Chang; Yeong Wook Song; Timothy J Vyse; John B Harley; Elizabeth E Brown; Jeffrey C Edberg; Robert P Kimberly; Rita M Cantor; Bevra H Hahn; Jennifer M Grossman; Betty P Tsao
Journal:  Ann Rheum Dis       Date:  2016-01-18       Impact factor: 19.103

Review 9.  Neuropsychiatric lupus: new mechanistic insights and future treatment directions.

Authors:  Noa Schwartz; Ariel D Stock; Chaim Putterman
Journal:  Nat Rev Rheumatol       Date:  2019-03       Impact factor: 20.543

10.  An Intervention to Reduce Psychosocial and Biological Indicators of Stress in African American Lupus Patients: The Balancing Lupus Experiences with Stress Strategies Study.

Authors:  Edith M Williams; Megan Penfield; Diane Kamen; James C Oates
Journal:  Open J Prev Med       Date:  2014-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.